Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.47 |
| ▸ | PHGDH | O43175 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251327 | 0.90 | SMN1; SMN2 (0.62) | SMN1; SMN2MAPTALDH1A1LMNATSHR | |
| SCHEMBL4244132 | 0.89 | MEN1 (0.56) | SMN1; SMN2MAPTCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL4245119 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTLMNAHTTGRM2 | |
| SCHEMBL4244480 | 0.75 | LMNA (0.55) | MAPTALDH1A1LMNATSHRHTT | |
| SCHEMBL4245787 | 0.74 | MAPT (0.67) | SMN1; SMN2MAPTALDH1A1LMNAHTT | |
| SCHEMBL4395226 | 0.74 | MAPT (0.67) | SMN1; SMN2MAPTALDH1A1LMNAHTT | |
| SCHEMBL12204385 | 0.73 | MEN1 (0.60) | MAPTALDH1A1LMNATSHRHTT | |
| SCHEMBL5199448 | 0.72 | DRD2 (0.55) | SMN1; SMN2MAPTALDH1A1LMNATSHR | |
| SCHEMBL4246303 | 0.72 | HTR1A (0.45) | SMN1; SMN2MAPTALDH1A1LMNATSHR | |
| SCHEMBL4252387 | 0.72 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTLMNAGRM2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | disclosed |
| EP-2057124-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM, LLC (BM) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008011611-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | SMN1; SMN2 3497/4885MAPT 3880/4885CYP2C9 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.